Eli Lilly's Next Weight-Loss Drug Could Outperform Zepbound

Eli Lilly (NYSE: LLY) is preparing to launch a new weight-loss drug that could surpass its existing drug Zepbound (tirzepatide), according to a report from Motley Fool. The new drug, still in development, has shown encouraging results in clinical trials, reinforcing the company's leadership in the expanding obesity treatment market.

The Product

The new drug, yet unnamed, belongs to the GLP-1 receptor agonist class, the same as Zepbound. However, it is designed to be more effective in inducing weight loss with fewer side effects. Early data suggests it could help patients lose up to 25% more weight compared to current treatments.

Pricing and Availability

Eli Lilly has not announced the price or launch date for the new drug. It is expected to be available by prescription only after FDA approval, which may take two years or more.

Competition

Eli Lilly faces strong competition from Novo Nordisk (NYSE: NVO), which produces Wegovy and Ozempic. Other companies like Pfizer and Amgen are also developing similar drugs. However, the new drug's superior efficacy could give Eli Lilly a significant competitive edge.

Potential Impact on the Company

If successful, the new drug could significantly boost Eli Lilly's revenue in the multibillion-dollar obesity market. Zepbound currently generates over $5 billion annually. Success of the new drug could add billions more, potentially lifting LLY stock.